Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
EDT.TO
SELLREMOVESpectral Medical Inc. · Healthcare · Canada · $282M · Avg Vol: $45K/d
Spectral Medical is a micro-cap medical device company with binary clinical trial risk, failing our quality and moat requirements.
COMPANY DESCRIPTION
Spectral Medical Inc. is a clinical-stage medical device company focused on developing and commercializing therapeutics for sepsis and septic shock. The company's competitive moat is anchored by its PMX hemoperfusion cartridge, which holds exclusive U.S. rights and is the only late-stage device targeting endotoxin removal in septic shock. It operates as a high-barrier-to-entry developer addressing a critical, unmet medical need in intensive care medicine.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 1.2M | 1.1M | 1.6M | 1.7M | 13.6% |
| EPS | -0.03 | -0.04 | -0.04 | -0.11 | — |
| Shares | 278.5M | 278.6M | 284.3M | 292.6M | +5.0% |
| Debt | 2.9M | 6.0M | 10.5M | 15.2M | 74.2% |
| Equity | -1.8M | -11.7M | -19.4M | -49.2M | — |
| Op CF | -7.0M | -7.6M | -6.2M | -6.7M | — |
| Inv CF | -23,289 | -0.1M | -19,055 | -0.1M | — |
| Fin CF | 6.7M | 3.8M | 6.3M | 7.6M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EDT.TO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EDT.TO | Spectral Medical Inc.(you) | $282M | 28 | SELL |
| PROF | Profound Medical Corp. | $251M | 24 | SELL |
| HITI | High Tide Inc. | $205M | 25 | SELL |
| EPRX.TO | Eupraxia Pharmaceuticals Inc. | $415M | 26 | SELL |
| ACB.TO | Aurora Cannabis Inc. | $180M | 30 | SELL |
| OGI | Organigram Global Inc. | $138M | 31 | SELL |
| WEED.TO | Canopy Growth Corporation | $501M | 21 | SELL |
| TLRY.TO | Tilray Brands, Inc. | $781M | 29 | SELL |
| CRDL.TO | Cardiol Therapeutics Inc. | $123M | 22 | SELL |
| HELP | Cybin D/B/A Helus Pharma | $245M | 6 | STRONG SELL |
Peer medians: ROE -44.7% · P/E 14.3x · Gross margin 32.9%